Table 1: IC50 values (mean ± SEM) of shikonin for a panel of 15 different sensitive and resistant cancer cell lines after 24and 48 h as assayed by resazurin reduction assay.

Cell lineCancer typeShikonin
IC50 [μM] (24 h)IC50 [μM] (48 h)

U937Histiocytic leukemia cell line0.30 ± 0.0030.19 ± 0.003
CCRF-CEMAcute lymphocytic leukemia cell line0.37 ± 0.010.24 ± 0.001
CEM/ADR5000*Acute lymphocytic leukemia cell line0.36 ± 0.050.38 ± 0.01
HL-60Acute myelocytic leukemia cell line0.39 ± 0.010.42 ± 0.001
HL-60/AR*Acute myelocytic leukemia cell line0.95 ± 0.0030.47 ± 0.001
MCF-7Breast carcinoma cell line9.05 ± 0.0810.51 ± 0.03
SK-BR-3Breast adenocarcinoma cell line9.21 ± 0.088.70 ± 0.03
MDA-MB-231/pcDNA3Breast carcinoma cell line1.23 ± 0.030.88 ± 0.03
MDA-MB-231/BCRP*Breast carcinoma cell line2.61 ± 0.061.48 ± 0.04
786-OKidney carcinoma cell line9.44 ± 0.138.03 ± 0.06
SW-1116Colorectal carcinoma (GIII) cell line6.63 ± 0.094.42 ± 0.06
HCT-116Colorectal carcinoma4.74 ± 0.078.54 ± 0.01
SW680Colorectal carcinoma7.21 ± 0.132.96 ± 0.06
Capan1Pancreas adenocarcinoma cell line7.23 ± 0.286.21 ± 0.14
SUIT-2Pancreatic carcinoma cell line12.92 ± 0.3518.50 ± 0.09

*MDR cancer cell lines with various drug resistances.